help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by AGUILAR, R. V.
Right arrow Articles by FARBER, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by AGUILAR, R. V.
Right arrow Articles by FARBER, H. W.

Am. J. Respir. Crit. Care Med., Volume 162, Number 5, November 2000, 1846-1850

Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension

ROBIN V. AGUILAR and HARRISON W. FARBER

The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts

Although HIV-associated pulmonary hypertension and primary pulmonary hypertension (PPH) are clinically and histologically similar, treatment options for the former are limited. Treatment with calcium channel blockers (CCB), proven to be beneficial in a subset of patients with PPH, has been disappointing in HIV-associated pulmonary hypertension and there are no data examining the effects of long-term epoprostenol in this entity. Six patients with severe HIV-associated pulmonary hypertension were treated with continuous intravenous epoprostenol infusions. Acute infusion of epoprostenol resulted in a significant (p < 0.05) decrease in mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) of 16.4 and 32.7%, respectively, and a significant (p < 0.05) increase in mean cardiac output (CO) of 36.9%. At 1 yr, mean PAP and PVR had decreased by 21.7 and 54.9% (p < 0.05), respectively, and mean CO had increased by 51.4% (p < 0.05) when compared with baseline values. Repeat catheterizations of three patients at 2 yr and one patient at 40 mo demonstrated further improvement or maintenance of hemodynamics. In addition, NYHA functional class improved in all patients. We conclude that epoprostenol infusion is effective in improving hemodynamic and functional status in this cohort of six patients with HIV-associated pulmonary hypertension acutely and long-term.




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619.
[Full Text] [PDF]

Home page
 CirculationHome page
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation, April 28, 2009; 119(16): 2250 - 2294.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
M. D. McGoon and G. C. Kane
Pulmonary Hypertension: Diagnosis and Management
Mayo Clin. Proc., February 1, 2009; 84(2): 191 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. Degano, A. Yaici, J. Le Pavec, L. Savale, X. Jais, B. Camara, M. Humbert, G. Simonneau, and O. Sitbon
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Eur. Respir. J., January 1, 2009; 33(1): 92 - 98.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. Butrous, H. A. Ghofrani, and F. Grimminger
Pulmonary Vascular Disease in the Developing World
Circulation, October 21, 2008; 118(17): 1758 - 1766.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Gomberg-Maitland and H. Olschewski
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Eur. Respir. J., April 1, 2008; 31(4): 891 - 901.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
A. E Lammers, A. A Hislop, Y. Flynn, and S. G Haworth
Epoprostenol treatment in children with severe pulmonary hypertension
Heart, June 1, 2007; 93(6): 739 - 743.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation, September 26, 2006; 114(13): 1417 - 1431.
[Full Text] [PDF]

Home page
 HeartHome page
G Barbaro, A Lucchini, A M Pellicelli, B Grisorio, G Giancaspro, and G Barbarini
Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension.
Heart, August 1, 2006; 92(8): 1164 - 1166.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 NEJMHome page
M. Humbert, O. Sitbon, and G. Simonneau
Treatment of Pulmonary Arterial Hypertension
N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436.
[Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 35S - 62S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Bresser, P.F. Fedullo, W.R. Auger, R.N. Channick, I.M. Robbins, K.M. Kerr, S.W. Jamieson, and L.J. Rubin
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Eur. Respir. J., April 1, 2004; 23(4): 595 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H.A. Ghofrani, G. Friese, T. Discher, H. Olschewski, R.T. Schermuly, N. Weissmann, W. Seeger, F. Grimminger, and J. Lohmeyer
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension
Eur. Respir. J., February 1, 2004; 23(2): 321 - 326.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. Nunes, M. Humbert, O. Sitbon, J. H. Morse, Z. Deng, J. A. Knowles, C. Le Gall, F. Parent, G. Garcia, P. Herve, et al.
Prognostic Factors for Survival in Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1433 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Galie, A. Manes, and A. Branzi
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Eur. Respir. J., October 1, 2002; 20(4): 1037 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. Barbaro
Cardiovascular Manifestations of HIV Infection
Circulation, September 10, 2002; 106(11): 1420 - 1425.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Galie, M. Humbert, J.-L. Vachiery, C. Vizza, M. Kneussl, A. Manes, O. Sitbon, A. Torbicki, M. Delcroix, R. Naeije, et al.
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1496 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin
New Treatments for Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 AIDS Clin CareHome page
HIV-Associated Pulmonary Hypertension
AIDS Clinical Care, June 1, 2001; 2001(601): 6 - 6.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  CCM abstracts